Joint Pain Forum – News you can use!
AlphaRx Announces Selection
Of ARX828, A Novel INOS Inhibitor, For Advanced Preclinical Development
edited by Joint-Pain-Forum.com
AlphaRx Inc. (OTC BB: ALRX), a specialty pharmaceutical company announced that
its ARX828, an orally-administered, potent and selective inhibitor of iNOS
(Inducible Nitric Oxide Synthase), is advancing to preclinical studies to
support an investigational new drug (IND) application in 2008.
models of inflammation, the anti-inflammatory activity of ARX828 is
significantly higher than Indomethacin and as effective as Dexamethasone (a
steroidal drug), but without the side-effects associated with either of these
The Company has initiated two pivotal animal studies for ARX828
and expects to receive results from these studies for analysis, by end of
November. The Company's goal is to develop ARX828 for the treatment of
Rheumatoid Arthritis and Inflammatory Bowel Disease.
There is no treatment currently available to cure RA.
The goals of treatment are to relieve pain, reduce inflammation, slow down joint
damage and improve function. Most RA patients require some form of DMARD--these
include methotrexate, an anti-cancer agent or the TNF-blocking agents such as
Enbrel. The TNF-blocking agents only inhibit the inflammatory mediator, TNF, and
require parenteral administration.
www.Joint-Pain-Forum.com from original press release.
About Inflammatory Bowel Disease
Inflammatory bowel disease
encompasses two chronic diseases that cause inflammation of the intestines:
ulcerative colitis and Crohn's disease. It is estimated that 1,000,000 Americans
suffer from IBD. The primary goal of current treatment is to reduce and prevent
inflammation that triggers symptoms.
AlphaRx is a specialty pharmaceutical company utilizing
proprietary site-specific nanoparticulate drug delivery systems to develop novel
formulations of drugs that are insoluble or poorly soluble in water or have yet
to be administrable to the human body with an acceptable delivery method. The
Company also discovers and develops novel, small-molecule drugs for the
treatment of inflammatory diseases and neurodegenerative
Forward Looking Statements:
This release contains
forward-looking statements within the meaning and pursuant to the Safe Harbor
provisions of the Securities Litigation Reform Act of 1995 and involve risks and
uncertainties that may individually or mutually impact the matters herein
described, including but not limited to product development and acceptance,
manufacturing, competition, regulatory and/or other factors, which are outside
the control of the companies.
Map | CONTACT